IsoRay, Inc. (NYSEMKT: ISR)
IsoRay had an interesting time in the market last week. After announcing that their Cesium-131 was as effective as current treatments; but with less time needed and less side effects, the company’s stock soared mid-week. However, the day following the press release, Adam Feuerstein attacked the company; driving the price down. In recent articles, I explained that Feuerstein’s attack was baseless and that I expect the stock to start climbing again soon. Well that seems to have started to happen today. So below, we’ll talk about what we’re seeing in the market and why IsoRay seems like a great long term investment. So, let’s get right to it…
What We’re Seeing From IsoRay Stock Today
It seems as though investors have finally started to look past Feuerstein’s blatant and unwarranted attack on ISR as the stock is climbing again today. Currently (11:57), ISR is trading at $2.02 per share after a gain of 9.78% so far.
Why IsoRay Is Likely To Climb Moving Forward
While the stock is climbing today, I have come across a few people on Stock Twits that still think that ISR is destined to fall. However, I don’t think that’s the case. My opinion revolves around Cesium-131, a cancer treatment developed by the company that is not only effective, but less painful on the patient. Here are a few things that investors should know about Cesium-131…
- Unlike traditional chemo therapy and radiation, patients are not required to under go treatment using Cesium-131 for months. Instead, the treatment is administered only once.
- Side effects are a big deal when it comes to any cancer treatment. Under the current care, chemo and radiation treatments cause horrible side effects. Not only is the patient likely to experience lethargy, the radiation causes other painful effects. As a matter of fact, it’s not uncommon for the patient’s skin to blister and peel. Not to mention, severe nausea and pain all over are part of the package.
- For many patients, the most important thing is their families. However, under current radiation treatments, families could be harmed. That’s because the radioactive half-life of the isotopes used in today’s treatments are generally between 6 and 9 months; essentially making the patient radioactive to an extent. Therefore, those who spend large amounts of time with the patient are in danger of radiation related sickness. Fortunately however, with Cesium-131 that’s not a concern. The radioactive half life of the isotope used is only a few days; making it less dangerous for family and friends to spend time with patients.
Keeping these facts in mind, it’s hard to imagine that IsoRay wouldn’t turn a profit from their innovation in the treatment of cancer.
What Do You Think?
Where do you think ISR is headed and why? Let us know in the comments below!